The application of anthracyclines in anticancer therapy may result in accidental extravasation injury and can be a serious complication of their use. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of anthracyclines during intravenous administration. Until recently, there has been no effective treatment against the devastating effect of extravasated anthracycline. Preclinical and clinical studies are leading to the clinical implementation of dexrazoxane as the first and only proven antidote in anthracycline extravasation. In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries.
Introduction
The extravasation of vesicant cancer chemotherapeutic agents, especially anthracyclines, remains one of the most distressing complications that hematologists and oncologists face in cytostatic, intravenous (iv) chemotherapy. Tissue necrosis with skin ulceration is a possible outcome in the inadvertent extravasation of several cytotoxic drugs during iv administration. The management of this complication remains an important challenge in cancer patients. 1 Several methods including hyperbaric oxygen therapy and different antidotes have been proposed in this setting with the aim to prevent or reduce tissue necrosis. 2 In July 2006 the EMEA approved dexrazoxane (Savene ® ; TopoTarget A/S, Copenhagen, Denmark) and in September 2007 the FDA approved dexrazoxane (Totect ® ; TopoTarget A/S, Copenhagen, Denmark) for the treatment of extravasation of intranvenous (iv) anthracycline chemotherapy. 3, 4 In this paper the management of anthracycline extravasation with dexrazoxane will be reviewed.
Incidence of extravasation
The estimated incidence of extravasation injuries ranges from 0.1% to 6%. 5, 6 In a series from the MD Anderson Cancer center the incidence of extravasation ranged between 0.1% and 1.0 % (44 cases of 40,000 to 60,000 treatments). In these 44 patients, 12 patients suffered from a doxorubicin extravasation.
The implantation of venous access ports is intended to create a safe access to the venous system and thus avoid the likelihood of extravasation. 7, 8 However, the use of central venous access devices may reduce but does not eliminate the risk of extravasation. [9] [10] [11] [12] Although much safer than peripheral vein access, extravasation may also 
Classification of vesicant, irritant or non-vesicant chemotherapeutic agents
Based on their potential for causing local tissue injury, chemotherapeutic agents are classified as vesicant, irritant or non-vesicant.
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Vesicant drugs have the capability to induce the formation of blisters and/or cause tissue destruction (eg, anthracyclines, amsacrin cisplatin, epirubicin, idarubicin, mitomycin c, mitoxantrone, paclitaxel, vinca alkaloids).
Irritant drugs can cause pain at the injection site or along the vein with or without an inflammatory reaction. Some of these agents have the potential to cause soft tissue ulcers only if a large amount cytotoxic agent solution is extravasated (eg, carboplatin, bendamustine, dacarbacin, docetaxel, etoposide, gemcitabine, ifosfamide, melphalan, topotecan).
Non-vesicant drugs, if extravasated, rarely produce acute reaction of tissue necrosis (eg, asparaginase, bleomycin, cyclophosphamide, cytarabine, fluorouracil, folinic acid, irinotecan, methotrexate, rituximab, thiopeta).
Clinical course of extravasation of vesicant drugs and of anthracyclines
An anthracycline extravasation is characterized by swelling and redness and is often very painful. Over a period of days or weeks this may progress to tissue necrosis producing tissue sloughing and ulceration with large wounds requiring surgical debridement and/or skin grafts. [18] [19] [20] Anthracyclines can persist in tissues for weeks or even months after extravasation. Furthermore, the local area of extravasation is at high risk of infection, because of both the local necrosis and in general by the impaired immunological state of most patients receiving this kind of treatment. 13, 21 The progression rate to ulceration of significant anthracycline extravasation ranges between 25% and 50%. 22, 23 The tissue damage may progress over days and weeks, causing pain and increasing the risk of infection, joint destruction, lesions of nerves and permanent dysfunctional and cosmetic changes in the involved area. Even the need for amputating the extremity is possible in case of anthracycline extravasation.
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Dexrazoxane
The approval of dexrazoxane was based on efficacy studies conducted in Europe to evaluate dexrazoxane as a post-extravasation treatment. 28, 29 Also several case reports about the successful treatment with dexrazoxane had been published. 8, 30 In summary, in each study the observed treatment frequency and severities of tissue damage appeared to be reduced significantly by dexrazoxane infusions given after anthracycline extravasation.
Chemistry of dexrazoxane
Dexrazoxane (ICRF-187) can be considered to be a neutral pro-drug analogue to the tetra-acid metal chelator EDTA. Chemically, dexrazoxane is 2,6-piperazinedione,4,4'- Figure 1 shows the chemical structure.
The molecular formula is C 11 H 16 N 4 O 4 ; the molecular weight is 268.3. Dexrazoxane is a white to off-white powder, with a melting point of 194 ± 3°C. It is soluble in dioxane and 0.1 N HCl, sparingly soluble in water, tetrahydrofuran, citrate buffer at pH 4.0, phosphate buffer at pH 7.0, and borate-potassium chloride sodium hydroxide buffer at pH 9.0. The acid dissociation constants, pKa, are 2.5 (for the tertiary piperazine nitrogen) and 9.7 (for the nitrogen imide). The log P is -2.135.
Mechanism of action
The mechanism by which dexrazoxane diminishes tissue damage resulting from the extravasation of anthracycline drugs is unknown.
However, two ways of action are discussed: 
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Dexrazoxane is able to penetrate the cell membrane and is degraded to ADR-925 by intracellular hydrolysis. ADR-925 is a strong chelating agent, which is able to form stabile complexes with iron, copper and other metal ions and also able to remove metal ions from complexes of doxorubicin and these ions. 31, 32 If oxidative stress caused by metal ions is assumed to cause tissue damage in anthracycline extravasation, chelating agents such as ADR-925 or EDTA should be able to reduce the level of damage after extravasation. In mice this effect could not be detected in systemic and intralesional use of EDTA or ADR-925. 33 It has been shown that dexrazoxane reversibly inhibits topoisomerase II. 34 However, it is difficult to identify a mechanism by which this could occur, as these tissues are not rapidly proliferating and contain only low levels of topoisomerase II. This is also underlined by the fact that two other non-chelating catalytic agents, merbarone and aclarubicin, also inhibitors of topoisomerase II, failed to prevent anthracycline-induced extravasation injuries in animals.
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Pharmacokinetics/pharmacodynamics
The pharmacokinetics of dexrazoxane initially have been studied in patients with advanced cancer having normal renal and hepatic function. Generally, the pharmacokinetics of dexrazoxane can be adequately described by an open two-compartment model with first-order elimination. Dexrazoxane has been administered as a 15-minute infusion over a dose range of 60 to 900 mg/m 2 with 60 mg/m 2 of doxorubicin, and at a fixed dose of 500 mg/m 2 with 50 mg/m 2 doxorubicin. 28, 35, 36 The disposition kinetics of dexrazoxane are doseindependent, as shown by a linear relationship between the area under plasma concentration-time curves and administered doses ranging from 60 to 900 mg/m 2 . The important pharmacokinetic parameters of dexrazoxane are listed in Table 1 .
Qualitative metabolism studies with dexrazoxane have confirmed the presence of unchanged drug, a diacid-diamide cleavage product, and two monoacid-monoamide ring products in the urine of animals and man.
The metabolite levels were not measured in the pharmacokinetic studies.
Urinary excretion plays an important role in the elimination of dexrazoxane. In vitro studies have shown that dexrazoxane is not bound to plasma proteins.
Accumulation of dexrazoxane has been the main point of interest in study TT04 which followed the first two multicenter studies (TT01 and TT02) examining the efficacy of dexrazoxane in preventing ulcerations. Levels of dexrazoxane have been measured during the 3-day scheme of application (1000, 1000 and 500 mg/m²) in patients suffering from an anthracycline extravasation. Six patients could be enrolled in this pharmacokinetics study. An accumulation of dexrazoxane could not be found any of these patients.
Drug interactions
There were no significant changes in the pharmacokinetics of doxorubicin (50 mg/m 2 ) and its predominant metabolite, doxorubicinol, in the presence of dexrazoxane (500 mg/m 2 ) in a crossover study in cancer patients.
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"Drug history" in regard to extravasation
In 2000 the first report on experimental subcutaneous (sc) injuries in mice caused by anthracycline successfully treated with dexrazoxane was published by Langer et al. 34 At this time dexrazoxane was registered only as a cardio-protective agent (Zinecard ® ; Pfizer; Cardioxane ® ; Novartis) against anthracycline-induced cardiotoxicity. In this paper, the authors discussed the topoisomerase II interaction as the inhibitory mechanism for its efficacy.
Also in 2000 the same authors reported two clinical cases of successful anthracycline extravasation treatment with dexrazoxane. In one case the patient experienced extravasation of epirubicin into the forearm; in the other case a total of 149 mg of doxorubicin infiltrated subcutaneously in the chest wall due to port needle displacement. Both patients received treatment with dexrazoxane 1000 mg/m² administered intravenously on day 1 and 2, and 500 mg/m² on day 3. As a result, no surgical intervention was required and at 3 months of follow up neither of the patients showed sequelae. 
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As a consequence of these findings a prospective clinical multi-center study was initiated.
Non-clinical studies with dexrazoxane
In an earlier series of preclinical studies, it was demonstrated that dexrazoxane administration soon after sc injection of doxorubicin, daunorubicin or idarubicin significantly reduces or prevents the formation of cutaneous lesions in mice. 3, 33, 34, 38 Clinical studies with dexrazoxane (TT01/TT02)
The results of two prospective multi-center. single-arm, open-label phase II/III clinical trials (TT01 and TT02) to evaluate the efficacy of iv dexrazoxane in the prevention of severe anthracycline-induced extravastion injuries have been published recently. 28 The primary endpoints of these two studies were preventing patients from undergoing surgical debridement of the affected area as well as preventing development of sequelae. Secondary endpoints were prevention of postponement of the scheduled cancer treatment and evaluation of tolerability and safety of dexrazoxane. To assure "real extravasation" of anthracyclines the diagnosis of extravasation had to be confirmed by positive fluorescence microscopy in at least one biopsy of the affected region. Local cooling of the extravasation site was permitted, but not within 15 minutes before the application of dexrazoxane, whereas local treatment with dimethylsulfoxide (DMSO) or steroids were not allowed.
The 3-day treatment schedule with dexrazoxane consisted of a daily dose of 1000 mg/m² on day 1-2 and 500 mg/m² on day 3. The infusion had to be given in the opposite arm of the extravasation site and was administered as soon as possible and no longer than 6 hours after the extravasation accident.
In both studies, 54 patients, mainly women with breast cancers, were included in the final analysis. The results of the combined studies showed that in 53 of 54 (98.2%) included patients, treatment with dexrazoxane prevented necrosis requiring surgical intervention. Only one patient (1.8 %) had to undergo surgical debridement. Thirty-eight patients (71.0%) were able to continue their scheduled chemotherapy without delay. In addition to bone marrow suppression, as expected from the fact that the extravasation happened during a chemotherapy course, temporarily infusion site pain (19%), mild sensory disturbance (17%), nausea, vomiting, diarrhea, stomatitis and transient alteration in liver enzymes have been observed. All adverse events were rapidly reversible. Although difficult to access due to parallel chemotherapy application, the safety profile of dexrazoxane appears to be good. In Table 2 the sequelae of the combined studies at the 3-month follow-up are shown.
There have also been single cases of intrapleural extravasation of epirubicin caused by catheter tip misplacement that have been successfully treated with dexrazoxane.
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Dosage and administration of dexrazoxane
Dexrazoxane should be given once daily for three consecutive days. The first infusion has to be initiated as soon as possible and within the first six hours after extravasation. 28 The recommended doses are as suggested by Mouridsen: Dexrazoxane should be administered as an iv infusion over 1 to 2 hours in a large caliber vein in an extremity/area other than the one affected by the extravasation. 39 Cooling procedures such as dry cold packs should be removed from the area at least 15 minutes before the infusion of dexrazoxane in order to allow sufficient blood flow in the area of extravasation. Treatment on day 2 and day 3 should start at the same time (± 3 hours) as on the first day.
Precautions
When administered to patients receiving anthracyclinecontaining cytotoxic therapy, additive cytotoxicity may occur, as dexrazoxane is a cytotoxic drug itself. Therefore, hematological monitoring should be performed. Reversible elevations of liver enzymes may occur with dexrazoxane.
DMSO should not be used in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation 40 (see below). Women who have the potential to become 
Dexrazoxane and DMSO
Before the introduction of dexrazoxane the standard treatment of anthracycline extravasation was the application of DMSO with or without cortisone. 41, 42 Therefore the question was raised if the addition of DMSO to dexrazoxane in extravasation injury would be beneficial. Langer et al compared the efficacy of topical DMSO and systemic dexrazoxane as monotherapy as well as in combination against anthracycline-induced ulceration in mice. 40 The addition of topical DMSO to the systemic dexrazoxane treatment resulted in the occurrence of wounds in 6 of 9 (66%) of the mice compared to none for dexrazoxane alone. The authors concluded that the addition of topical DMSO to iv dexrazoxane treatment resulted in decreased efficacy. Although the study was conducted in animals, the results do not support the use of DMSO in combination with dexrazoxane.
Dexrazoxane and liposomal anthracyclines
In the study by Mouridsen only one patient received liposomal anthracycline, who did respond but not as well as the other patients. 28 From this single case it is impossible to draw any firm conclusions; however it is conceivable that dexrazoxane may not be as effective in these patients, as the initial injury is masked by the liposomal envelope surrounding the anthracycline.
In case reports about extravasations of liposomal anthracyclines, their ulcerative potency is described as being much weaker than that of non-liposomal anthracyclines. The actions taken after extravasation did not include the use of dexrazoxane. 43, 44 Nevertheless, the ulcerative potential of liposomal anthracyclines might be a matter of the amount of extravasated agent, as small amounts did not cause ulcers (irritant) but larger quantities of extravasated liposomal cytotoxic drugs caused severe tissue defects (vesicant). 45 As a possible cause of this reduced harmfulness, an evacuation of liposomal drugs via the lymphatic system has been proved in mice models. 46 
Conclusions
Dexrazoxane is an important development in the management of anthracycline extravasation. In case of a positively identified anthracycline extravasation it should be available within 6 hours and administered in the licensed 3-day course. However, the introduction of this new antidote needs to be audited for its efficacy in actual practice and further research work should be performed to better refine and develop its use.
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